Page results
-
Once you have completed treatment for breast cancer at UCLH you will enter a period of follow-up care. Follow-up is an important way of monitoring your health. It allows us to identify any signs that…
-
This booklet is designed for teenagers and young people. It explains what you can expect when you finish your treatment for Hodgkin lymphoma.
-
You have been given this information because your unborn baby (fetus) has been diagnosed with spina bifida. This news must have been stressful for you and your partner/family, and you will have to…
-
The Leishmaniasis Multidisciplinary Team (MDT) The leishmaniasis MDT aims to support clinicians around the UK in the investigation and management of patients with suspected or confirmed…
-
This page is for patients who have been offered CT guided spinal steroid injections.
-
Thalassaemia is a group of inherited blood conditions where the part of the blood known as haemoglobin is abnormal.
-
This page explains what adrenal surgery is and provides information about what it involves. It also provides information about the risks and benefits of adrenal surgery.
-
UCLH is a designated specialist centre for the treatment of head and neck cancer for people in north and east London and west Essex.
-
Sickle cell disorder is the most common genetic (inherited) disorder in the United Kingdom.
-
The UCLH Lymphoma multidisciplinary team (MDT) provides specialist care for people with lymphoma.
File results
-
FOI/2023/0356 - Current wait time for referral to treatment with a consultant for osteoporosis
-
FOI/2023/0361 - List of all the doctors and consultants working within UCLH
-
FOI/2023/0363 - External management/ business consultants spend/ fees to recruitment agencies for 2023
-
FOI/2023/0368 - Apprenticeship Levy - 2019-20 to 2022/23 (Part 1)
-
FOI/2019/484 Homless patients admitted to ED
-
FOI/2019/411 ICT and Facilities contact details
-
FOI/2019/449 Specialist Stoke Unit at the Trust
-
FOI/2019/457 Invoiced income to non-EU overseas visitors
-
FOI/2019/468 Rheumatoid Arthritis biologic pathway
-
FOI/2019/516 TMS and SCS protocols, guidelines and treatment pathways